Biopharma Dealmakers A supplement to Nature Biotechnology and Nature Reviews Drug Discovery
The March 2014 issue of Biopharma Dealmakers showcases companies with partnering opportunities. This week, find out about how you can collaborate with Amunix Operating Inc.
Learn the Fundamentals of Entrepreneurship from the Stanford Graduate School of Business in Paris
Informational Webinar on Monday, May 5 at 7:00pm (CEST) Stanford Graduate School of Business Professor Yossi Feinberg will share his insights on the core elements of entrepreneurship and provide a taste of what to expect from Stanford Ignite - Polytechnique.
Peeking inside AMD Benjamin Boettner doi:10.1038/scibx.2014.476 Conflicting results from prior studies made it unclear whether IL-18 was a cause of or a potential therapy for age-related macular degeneration. A tiebreaker study suggests the latter, showing that the cytokine was at least as effective as a VEGF inhibitor in mouse models of wet AMD. Full Text | PDF
Scripps looks outward Chris Cain doi:10.1038/scibx.2014.477 The Scripps Research Institute has formed a separate corporation called Scripps Advance that will house assets and IP related to discrete early stage research projects. Johnson & Johnson's California Innovation Center is on board as Scripps Advance's first partner. Full Text | PDF
Stem cell disarray C. Simone Fishburn doi:10.1038/scibx.2014.478 The NIH is rethinking its strategy for translating stem cell therapies. Stakeholders hope the message will be that the NIH should focus less on drug development and more on standardizing procedures and protocols. Full Text | PDF
Superhuman mice Tracey Baas doi:10.1038/scibx.2014.479 The paradox of current mouse-based antibody platforms is that the Ig gene manipulations used to generate the mice can limit the animals' ability to produce robust antibody responses. Kymab and Regeneron have now published details about how their newest mouse platforms improve antibody diversity and affinity. Full Text | PDF
Serum/glucocorticoid regulated kinase 1 (SGK1) doi:10.1038/scibx.2014.480 Cell culture and mouse studies suggest inhibiting SGK1 could help treat asthma. Full Text | PDF
Calcium calmodulin-dependent protein kinase IV (CAMK4) doi:10.1038/scibx.2014.481 Studies in human samples and mice suggest inhibiting CAMK4 could help treat lupus. Full Text | PDF
c-Myc (MYC) doi:10.1038/scibx.2014.482 In vitro studies suggest blocking both full-length MYC and its N-terminal cleavage product could help treat cancer. Full Text | PDF
CTLA-4 (CD152); inducible T cell co-stimulator (ICOS) doi:10.1038/scibx.2014.483 Mouse studies suggest combining anti-CTLA-4 antibodies plus vaccines that increase ICOS could help treat various cancers. Full Text | PDF
Integrin αVβ3 (CD51/CD61) doi:10.1038/scibx.2014.484 In vitro studies have identified selective integrin αVβ3 antagonists that could be useful for treating cancer. Full Text | PDF
p53 doi:10.1038/scibx.2014.485 In vitro and cell-based studies suggest combining an inhibitor of nonsense-mediated RNA decay and a promoter of premature stop-codon read-through could help treat cancer. Full Text | PDF
Receptor tyrosine kinase (RTK); VEGF-A doi:10.1038/scibx.2014.486 Mouse and cell culture studies identified apratoxin analogs that could be useful for treating cancer. Full Text | PDF
Retinoid X receptor-α (RXRA; RXRα) doi:10.1038/scibx.2014.487 In vitro and mouse studies identified derivatives of the generic NSAID sulindac that specifically inhibit RXRα and could help treat cancer. Full Text | PDF
IL-1 receptor–like 1 (IL1RL1; ST2); IL-33 (NF-HEV) doi:10.1038/scibx.2014.488 Mouse and cell culture studies suggest inhibiting IL-33 signaling could help treat Gleevec imatinib–resistant CML. Full Text | PDF
Jumonji domain containing 6 (JMJD6) doi:10.1038/scibx.2014.489 Mouse and in vitro studies suggest inhibiting JMJD6 signaling could be useful for treating colon cancer. Full Text | PDF
IL-2 doi:10.1038/scibx.2014.490 Mouse studies suggest a complex composed of an IL-2 mAb and IL-2 could help improve the ability of cancer vaccines to prevent relapse in patients with lymphoma. Full Text | PDF
IL-17 doi:10.1038/scibx.2014.491 Mouse studies suggest blocking IL-17 could help treat or prevent inflammatory chronic obstructive pulmonary disease (COPD)-associated NSCLC. Full Text | PDF
Lactate dehydrogenase A (LDHA); K-Ras (KRAS); epidermal growth factor receptor 1 (EGFR1; HER1; ErbB1) doi:10.1038/scibx.2014.492 Mouse studies suggest inhibiting LDHA could help treat KRAS- and EGFR1-mutant NSCLC. Full Text | PDF
Amylase α1A (AMY1A); AMY1B; AMY1C doi:10.1038/scibx.2014.493 Genetic studies identified an association between copy number variants of the salivary amylase genes and obesity that could lead to new therapeutics. Full Text | PDF
DENN/MADD domain containing 1A (DENND1A) doi:10.1038/scibx.2014.494 Patient and cell culture studies suggest a DENND1A isoform could be a marker and target for PCOS. Full Text | PDF
Not applicable doi:10.1038/scibx.2014.496 In vitro studies suggest inducing an IgG3 response against HIV antigens could help create protective immunity against infection. Full Text | PDF
Potassium channel Kir4.1 (KCNJ10) doi:10.1038/scibx.2014.497 Mouse studies suggest increasing Kir4.1 expression could help treat HD. Full Text | PDF
Chondroitin sulfate proteoglycan (CSPG) doi:10.1038/scibx.2014.498 Rat studies suggest lentivirus-delivered, mammalian-optimized chondroitinase ABC (ChABC) could help treat SCI. Full Text | PDF
Arachidonate 15-lipoxygenase (ALOX15; 15-LOX) doi:10.1038/scibx.2014.499 In vitro and mouse studies suggest a new class of ALOX15 inhibitors could help treat stroke. Full Text | PDF
Protein kinase cAMP-dependent catalytic-α (PRKACA) L205R doi:10.1038/scibx.2014.500 Genetic sequencing studies identified an activating PRKACA mutation in Cushing's disease that could help model the disorder. Full Text | PDF
Src; tuberous sclerosis complex tumor suppressor 2 (TSC2) doi:10.1038/scibx.2014.501 Studies in patient samples, cell culture and mice suggest inhibiting Src kinase activity could help treat the progressive cystic lung disease lymphangioleiomyomatosis (LAM). Full Text | PDF
Engineered skeletal muscle tissue to model diseased muscle doi:10.1038/scibx.2014.502 Engineered skeletal muscle could help identify new muscle-regenerating therapies. Full Text | PDF
Engineered Nicotiana benthamiana to produce glycosylated IgMs doi:10.1038/scibx.2014.503 Engineered N. benthamiana could generate glycosylated IgMs to treat human diseases. Full Text | PDF
Ex vivo wingless-type MMTV integration site family member 7A (WNT7A) treatment of myogenic cells prior to muscle cell transplantation to enhance both fusion with myofibrils and muscle function doi:10.1038/scibx.2014.504 Cell culture and mouse studies suggest ex vivo treatment with WNT7A could improve stem cell therapies for muscular dystrophies. Full Text | PDF
Small molecule modulators of G protein–coupled receptor 183 (GPR183; EBI2) doi:10.1038/scibx.2014.505 Small molecule modulators of EBI2 could be useful for probing the function of the receptor and its relevance to human diseases. Full Text | PDF
Combined use of luminescence imaging and MRI for real-time, in vivo, quantitative monitoring of drug release doi:10.1038/scibx.2014.506 A combined strategy using luminescence imaging and MRI could be useful for real-time, quantitative monitoring of drug release in vivo. Full Text | PDF
Spectral confocal reflectance microscopy for label-free myelin imaging doi:10.1038/scibx.2014.507 Studies in mice and human samples suggest spectral confocal reflectance microscopy could be a label-free method to image myelinated axons. Full Text | PDF
Asthma diagnostic based on neutrophil chemotaxis speed doi:10.1038/scibx.2014.508 A handheld microfluidic device that measures neutrophil chemotaxis speed could help diagnose asthma. Full Text | PDF
Solute carrier family 12 potassium-chloride transporter member 2 (SLC12A2; NKCC1)-based markers for schizophrenia doi:10.1038/scibx.2014.509 Genetic profiling studies suggest assessing variation in NKCC1 expression could help predict schizophrenia risk. Full Text | PDF
You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant)
Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA
Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston
Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS.
No comments:
Post a Comment